Introduction
============

Th17 cells are known to be crucial mediators of autoimmune inflammation. However, two distinct types of Th17 cells have recently been described, which differed in their ability to coproduce IL-10 or IFN-g due to differential polarizations requirements for IL-1b. Whether these distinct Th17 phenotypes translate into distinct Th17 cell functions and whether this has implications for human health or disease has not been addressed yet.

Objectives
==========

We hypothesized that IL-1b independent IL-10^+^Th17 cells have anti-inflammatory functions whereas IL-1b dependent IL-10^-^ Th17 cells are pro-inflammatory. Considering the crucial role of IL-1b in the pathogenesis of autoinflammatory syndromes, we hypothesized an IL-1b mediated loss of anti-inflammatory Th17 cell functions in Schnitzler Syndrome, an autoinflammatory disease.

Methods
=======

To assess pro- versus anti-inflammatory Th17 cell functions we performed suppression assays and tested the effects of IL-1b dependent and independent Th17 subsets on modulating pro-inflammatory cytokine secretion by monocytes. Schnitzler Syndrome patients were analyzed for changes in Th17 cell functions before and after therapy with IL-1b depleting drugs.

Results
=======

IL-10^+^ Th17 cells, which differentiated independently of IL-1b, have regulatory functions similar to Treg cells while IL-1b dependent IL-10^-^ Th17 cells have not. Both Th17 cell subsets differ in their ability to suppress T cell proliferation as well as in their ability modulate pro-inflammatory cytokine production by antigen presenting cells. In Schnitzler Syndrome, an autoinflammatory syndrome, overproduction of IL-1b translates into pro-inflammatory Th17 cell functions, which can be reversed by anti-IL-1b treatment.

Conclusion
==========

Th17 cells are not *per se* pro-inflammatory but can also have anti-inflammatory IL-10 mediated functions if generated independently of IL-1b. Our data introduce Th17 cell subsets as novel players in autoinflammation and thus novel therapeutic targets in autoinflammatory syndromes including other IL-1b mediated diseases. This demonstrates for the first time alterations in the adaptive immune system in autoinflammatory syndromes.
